Maexeni

Ethinylestradiol and Levonorgestrel, the active ingredients in Maexeni, are a combined oral contraceptive presented as a tablet for oral use. They work together to prevent pregnancy by inhibiting ovulation and altering cervical mucus and the endometrium. GNH USA supplies Maexeni as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maexeni, a combined oral contraceptive, is indicated for hormonal contraception to prevent pregnancy. - Contraception: prevents pregnancy by suppressing ovulation and modifying cervical mucus. - Family planning: provides reliable birth control for women of reproductive age. - Menstrual cycle regulation: helps achieve more predictable bleeding patterns and reduces menstrual discomfort.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: temporary swelling or discomfort. - Headache: occasional tension‑type headaches. - Spotting or breakthrough bleeding: irregular light bleeding. - Mood changes: irritability or mild mood swings. - Weight fluctuation: slight increase or fluid retention.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in veins. - Pulmonary embolism: clot migration to lung vessels. - Stroke: cerebrovascular accident due to clot or hemorrhage. - Myocardial infarction: heart attack risk, especially in smokers. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver tumor: rare hepatic adenoma development.

Before initiating Maexeni, consider the following precautions. - Cardiovascular assessment: evaluate risk factors such as hypertension, smoking, or clotting disorders. - Liver function: avoid use in patients with active liver disease or severe hepatic impairment. - Smoking status: advise women over 35 who smoke to discontinue use. - Missed dose management: provide clear instructions for handling forgotten tablets. - Concomitant medications: review other drugs that may affect efficacy or safety. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture and direct sunlight.

Maexeni may interact with several medicines that alter its effectiveness or safety. Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): markedly reduce contraceptive efficacy. - St. John’s wort: may decrease hormone levels, leading to breakthrough bleeding. - Certain antiepileptics (e.g., phenobarbital): lower plasma concentrations of the active ingredients.

Moderate Interactions (Monitor Closely): - Antifungals (e.g., ketoconazole, itraconazole): may increase hormone levels, raising side‑effect risk. - HIV protease inhibitors (e.g., ritonavir): can elevate plasma concentrations. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may modestly affect hormone metabolism. - Diuretics and antihypertensives: monitor blood pressure as hormonal changes can influence fluid balance.